191 related articles for article (PubMed ID: 7600540)
21. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
22. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
Butterworth BE
Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
[TBL] [Abstract][Full Text] [Related]
23. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
Butterworth BE; Conolly RB; Morgan KT
Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
[TBL] [Abstract][Full Text] [Related]
24. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
25. A decision tree approach for carcinogen risk assessment.
Butterworth BE; Eldridge SR
Prog Clin Biol Res; 1995; 391():49-70. PubMed ID: 8532737
[TBL] [Abstract][Full Text] [Related]
26. Chemically induced cell proliferation in carcinogenesis.
Butterworth BE; Popp JA; Conolly RB; Goldsworthy TL
IARC Sci Publ; 1992; (116):279-305. PubMed ID: 1428087
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive approach for integration of toxicity and cancer risk assessments.
Butterworth BE; Bogdanffy MS
Regul Toxicol Pharmacol; 1999 Feb; 29(1):23-36. PubMed ID: 10051416
[TBL] [Abstract][Full Text] [Related]
28. Reducing uncertainty in risk assessment by using specific knowledge to replace default options.
McClellan RO
Drug Metab Rev; 1996; 28(1-2):149-79. PubMed ID: 8744594
[TBL] [Abstract][Full Text] [Related]
29. Active cell death (apoptosis) and cellular proliferation as indicators of exposure to carcinogens.
Schulte-Hermann R; Bursch W; Marian B; Grasl-Kraupp B
IARC Sci Publ; 1999; (146):273-85. PubMed ID: 10353391
[TBL] [Abstract][Full Text] [Related]
30. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
31. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
[TBL] [Abstract][Full Text] [Related]
32. Risk assessment of peak exposure to genotoxic carcinogens: a pragmatic approach.
Bos PM; Baars BJ; van Raaij MT
Toxicol Lett; 2004 Jun; 151(1):43-50. PubMed ID: 15177639
[TBL] [Abstract][Full Text] [Related]
33. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective.
Bolt HM; Foth H; Hengstler JG; Degen GH
Toxicol Lett; 2004 Jun; 151(1):29-41. PubMed ID: 15177638
[TBL] [Abstract][Full Text] [Related]
34. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment.
Proctor DM; Gatto NM; Hong SJ; Allamneni KP
Toxicol Sci; 2007 Aug; 98(2):313-26. PubMed ID: 17426108
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
